Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 4,570,000 shares, a growth of 14.0% from the June 30th total of 4,010,000 shares. Based on an average daily volume of 190,800 shares, the days-to-cover ratio is presently 24.0 days. Currently, 10.7% of the company’s stock are sold short.
Wall Street Analyst Weigh In
GALT has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, April 9th. StockNews.com downgraded shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 18th.
Get Our Latest Report on Galectin Therapeutics
Institutional Investors Weigh In On Galectin Therapeutics
Galectin Therapeutics Price Performance
GALT traded up $0.01 on Monday, reaching $2.57. The company’s stock had a trading volume of 97,963 shares, compared to its average volume of 154,261. Galectin Therapeutics has a 1 year low of $1.35 and a 1 year high of $4.27. The business’s 50 day moving average is $2.54 and its 200 day moving average is $2.49. The stock has a market cap of $159.73 million, a price-to-earnings ratio of -3.50 and a beta of 0.63.
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, research analysts forecast that Galectin Therapeutics will post -0.66 earnings per share for the current fiscal year.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Read More
- Five stocks we like better than Galectin Therapeutics
- Comparing and Trading High PE Ratio Stocks
- Survey: Top 175 Fittest Retirement Locations in America
- What is the S&P/TSX Index?
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.